FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205865938> ?p ?o ?g. }

• W3205865938 abstract "Abstract Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently constitutes the leading and overwhelming health issue worldwide. In comparison with adults, children present milder symptoms, with most having an asymptomatic course. We hypothesized that COVID-19 infection has a negative impact on the continuation of chemotherapy and increases nonrelapse mortality. Material and methods This study was performed to assess the course of SARS-CoV-2 among children with hematological or oncological malignancies and its impact on cancer therapy. Records of SARS-CoV-2 infection in 155 children with malignancies from 14 Polish centers for pediatric hematology and oncology were collected and analyzed. Results SARS-CoV-2 replication was observed in 155 patients. Forty-nine patients were symptomatic, with the following being the most common manifestations: fever (31 patients), gastrointestinal symptoms (10), coryza (13), cough (13) and headache (8). In children who were retested, the median time of a positive PCR result was 16 days (range 1–70 days), but 12.7% of patients were positive beyond day + 20. The length of viral PCR positivity correlated with the absolute neutrophil count at diagnosis. Seventy-six patients did not undergo further SARS-CoV-2 testing and were considered convalescents after completion of isolation. Antibiotic therapy was administered in 15 children, remdesivir in 6, convalescent plasma in 4, oxygen therapy in 3 (1—mechanical ventilation), steroids in 2, intravenous immunoglobulins in 2, and heparin in 4. Eighty patients were treated with chemotherapy within 30 days after SARS-CoV-2 infection diagnosis or were diagnosed with SARS-CoV-2 infection during 30 days of chemotherapy administration. Respiratory symptoms associated with COVID-19 and associated with oxygen therapy were present in 4 patients in the study population, and four deaths were recorded (2 due to COVID-19 and 2 due to progressive malignancy). The probability of 100-day overall survival was 97.3% (95% CI 92.9–99%). Delay in the next chemotherapy cycle occurred in 91 of 156 cases, with a median of 14 days (range 2–105 days). Conclusions For the majority of pediatric cancer patients, SARS-CoV-2 infection does not result in a severe, life-threatening course. Our data show that interruptions in therapy are common and can result in suboptimal therapy." @default.
• W3205865938 created "2021-10-25" @default.
• W3205865938 creator A5004662081 @default.
• W3205865938 creator A5011903854 @default.
• W3205865938 creator A5012457465 @default.
• W3205865938 creator A5015485580 @default.
• W3205865938 creator A5016154411 @default.
• W3205865938 creator A5017620831 @default.
• W3205865938 creator A5020975466 @default.
• W3205865938 creator A5028124057 @default.
• W3205865938 creator A5029280043 @default.
• W3205865938 creator A5040158837 @default.
• W3205865938 creator A5040223708 @default.
• W3205865938 creator A5040758408 @default.
• W3205865938 creator A5041527330 @default.
• W3205865938 creator A5043166775 @default.
• W3205865938 creator A5051111839 @default.
• W3205865938 creator A5054356659 @default.
• W3205865938 creator A5056069165 @default.
• W3205865938 creator A5056705271 @default.
• W3205865938 creator A5060508370 @default.
• W3205865938 creator A5061924630 @default.
• W3205865938 creator A5064396176 @default.
• W3205865938 creator A5067854890 @default.
• W3205865938 creator A5068263698 @default.
• W3205865938 creator A5071752621 @default.
• W3205865938 creator A5071924829 @default.
• W3205865938 creator A5077705978 @default.
• W3205865938 creator A5078027655 @default.
• W3205865938 creator A5083841118 @default.
• W3205865938 creator A5085336702 @default.
• W3205865938 date "2021-10-11" @default.
• W3205865938 modified "2023-10-18" @default.
• W3205865938 title "COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study" @default.
• W3205865938 cites W1964189436 @default.
• W3205865938 cites W2189064098 @default.
• W3205865938 cites W3001118548 @default.
• W3205865938 cites W3007406215 @default.
• W3205865938 cites W3008028633 @default.
• W3205865938 cites W3011610993 @default.
• W3205865938 cites W3013495714 @default.
• W3205865938 cites W3013959692 @default.
• W3205865938 cites W3014571775 @default.
• W3205865938 cites W3015030076 @default.
• W3205865938 cites W3016005709 @default.
• W3205865938 cites W3016246665 @default.
• W3205865938 cites W3021274772 @default.
• W3205865938 cites W3025633253 @default.
• W3205865938 cites W3034651359 @default.
• W3205865938 cites W3037183278 @default.
• W3205865938 cites W3047119433 @default.
• W3205865938 cites W3047259961 @default.
• W3205865938 cites W3087134847 @default.
• W3205865938 cites W3087631173 @default.
• W3205865938 cites W3096967708 @default.
• W3205865938 cites W3104457017 @default.
• W3205865938 cites W3113340432 @default.
• W3205865938 cites W3120389648 @default.
• W3205865938 cites W3131532116 @default.
• W3205865938 cites W3134932663 @default.
• W3205865938 cites W3135699964 @default.
• W3205865938 cites W3136462056 @default.
• W3205865938 cites W3160396540 @default.
• W3205865938 doi "https://doi.org/10.1186/s13045-021-01181-4" @default.
• W3205865938 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8503711" @default.
• W3205865938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34635137" @default.
• W3205865938 hasPublicationYear "2021" @default.
• W3205865938 type Work @default.
• W3205865938 sameAs 3205865938 @default.
• W3205865938 citedByCount "17" @default.
• W3205865938 countsByYear W32058659382022 @default.
• W3205865938 countsByYear W32058659382023 @default.
• W3205865938 crossrefType "journal-article" @default.
• W3205865938 hasAuthorship W3205865938A5004662081 @default.
• W3205865938 hasAuthorship W3205865938A5011903854 @default.
• W3205865938 hasAuthorship W3205865938A5012457465 @default.
• W3205865938 hasAuthorship W3205865938A5015485580 @default.
• W3205865938 hasAuthorship W3205865938A5016154411 @default.
• W3205865938 hasAuthorship W3205865938A5017620831 @default.
• W3205865938 hasAuthorship W3205865938A5020975466 @default.
• W3205865938 hasAuthorship W3205865938A5028124057 @default.
• W3205865938 hasAuthorship W3205865938A5029280043 @default.
• W3205865938 hasAuthorship W3205865938A5040158837 @default.
• W3205865938 hasAuthorship W3205865938A5040223708 @default.
• W3205865938 hasAuthorship W3205865938A5040758408 @default.
• W3205865938 hasAuthorship W3205865938A5041527330 @default.
• W3205865938 hasAuthorship W3205865938A5043166775 @default.
• W3205865938 hasAuthorship W3205865938A5051111839 @default.
• W3205865938 hasAuthorship W3205865938A5054356659 @default.
• W3205865938 hasAuthorship W3205865938A5056069165 @default.
• W3205865938 hasAuthorship W3205865938A5056705271 @default.
• W3205865938 hasAuthorship W3205865938A5060508370 @default.
• W3205865938 hasAuthorship W3205865938A5061924630 @default.
• W3205865938 hasAuthorship W3205865938A5064396176 @default.
• W3205865938 hasAuthorship W3205865938A5067854890 @default.
• W3205865938 hasAuthorship W3205865938A5068263698 @default.
• W3205865938 hasAuthorship W3205865938A5071752621 @default.
• W3205865938 hasAuthorship W3205865938A5071924829 @default.
• W3205865938 hasAuthorship W3205865938A5077705978 @default.
• W3205865938 hasAuthorship W3205865938A5078027655 @default.

• next